2023-11-10-英砂智能_亿欧智库-2023年药物研发自动化实验室行业发展报告_79页_4mb

2023年药物研发自动化实验室行业发展报告 Summary

Key Findings

• Automated laboratories in pharmaceutical R&D enhance drug discovery and development by increasing efficiency, reducing costs, and improving accuracy through technologies like AI and high-throughput screening.
• The report outlines the evolution from 1-6th generation labs, demonstrating full automation up to the sixth generation, with Phase 7 envisioned for miniaturization.
• Core hardware includes robotics, liquid handling systems, high-throughput sequencing, and imaging, while software and AI enable data analysis and automation.
• Real-world case studies from institutions and companies (e.g., Illumina, Biotech, Pharmaceutical firms) highlight successful applications of automation in drug research.
• Future trends emphasize AI integration, reduced human involvement, and significant cost savings, with market forecasts suggesting substantial growth by 2035.

Generational Development

• 1-6th Generation Labs: Profiles the historical progression, focusing on how each generation addresses specific R&D challenges, such as error reduction and process optimization.

Core Technologies and AI Integration

• Automation islands integrate hardware for tasks like compound management and drug screening, with AI improving decision-making and data reusability.
• AI-driven approaches facilitate target discovery, compound optimization, and seamless automation, enhancing efficiency across drug development phases.

Future Trends and Market Outlook

• AI and deep learning enhance future automated labs, reducing drug development timelines and costs.
• The market is expected to reach approximately $718 billion by 2035, with applications expanding to miniaturized labs for individualized research scenarios.